Systemic inflammatory biomarkers may be useful in the differential diagnosis of primary central nervous system lymphoma, high-grade glioma
MONDAY, April 18, 2022 (HealthDay News) — Systemic inflammatory biomarkers may aid in differentiating primary central nervous system lymphoma (PCNSL) from high-grade glioma (HGG), according to a study published online April 4 in CNS Oncology.
Tejpal Gupta, M.D., from the Homi Bhabha National Institute in Mumbai, India, and colleagues calculated systemic inflammatory indices from pretreatment complete blood counts and liver function tests and compared them against histopathology as a reference standard among 42 patients with PCNSL and 16 with HGG.
The researchers observed significant differences in the mean values for absolute lymphocyte count and prognostic nutritional index between PCNSL and HGG patients. For absolute lymphocyte count and prognostic nutritional index, the area under the receiver operating characteristic curve in the diagnosis of PCNSL was 0.70 and 0.72, respectively, indicating fair and acceptable diagnostic accuracy.
“This exploratory first-of-a kind study assessed the utility of systemic inflammatory biomarkers derived from routine blood investigations in a cohort of patients with suspected PCNSL to differentiate them reliably from HGG with similar morphologic imaging,” the authors write.
Better Cardiovascular Health Inversely Linked to Overactive Bladder 
Retinal Imaging Can ID Atrial Fibrillation Years Before Diagnosis 
U.S. Adults May Not Understand Their Risk for Vascular Disease 
Screening + Online Cognitive Behavioral Therapy Program Aids Nurses" Mental Health 
Air Pollution Tied to Higher Risk for Suicide 
Psychiatrists Only Agree 55 Percent of the Time on Diagnoses 
2021 to 2026 Saw Increase in State Funding for Suicide Prevention 
People Using Illicitly Sourced Fentanyl Face Worse Outcomes Than Medically Sourced Users 
.jpg)